IBRX

ImmunityBio, Inc. develops investigational immunotherapies aimed at treating cancer and infectious diseases by activating both innate and adaptive immune responses. The company focuses on harnessing the immune system to create durable immune responses, with a clinical pipeline that includes therapies for bladder cancer, glioblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, and HIV. ImmunityBio operates primarily in the biotechnology sector, targeting patients in need of advanced cancer treatments and therapies that may reduce reliance on traditional chemotherapy.